213 related articles for article (PubMed ID: 17403806)
1. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
[TBL] [Abstract][Full Text] [Related]
2. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
Dranitsaris G; Stumpo C; Smith R; Bartle W
Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.
Schousboe JT; Brown GA
J Bone Joint Surg Am; 2013 Jul; 95(14):1256-64. PubMed ID: 23864173
[TBL] [Abstract][Full Text] [Related]
4. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
[TBL] [Abstract][Full Text] [Related]
6. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
[TBL] [Abstract][Full Text] [Related]
8. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant.
Samama CM; Vray M; Barré J; Fiessinger JN; Rosencher N; Lecompte T; Potron G; Basile J; Hull R; Desmichels D;
Arch Intern Med; 2002 Oct; 162(19):2191-6. PubMed ID: 12390061
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
[TBL] [Abstract][Full Text] [Related]
10. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement.
Marchetti M; Liberato NL; Ruperto N; Barosi G
Haematologica; 1999 Aug; 84(8):730-7. PubMed ID: 10458700
[TBL] [Abstract][Full Text] [Related]
11. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Kapoor A; Chuang W; Radhakrishnan N; Smith KJ; Berlowitz D; Segal JB; Katz JN; Losina E
Pharmacoeconomics; 2010; 28(7):521-38. PubMed ID: 20550220
[TBL] [Abstract][Full Text] [Related]
13. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
14. The role of low molecular weight heparin in total knee arthroplasty.
Iobst CA; Friedman RJ
Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
[TBL] [Abstract][Full Text] [Related]
15. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
Whang PG; Lieberman JR
Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
[TBL] [Abstract][Full Text] [Related]
16. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty.
Friedman RJ; Dunsworth GA
Clin Orthop Relat Res; 2000 Jan; (370):171-82. PubMed ID: 10660711
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?
Dahl OE; Bergqvist D; Cohen AT; Frostick SP; Hull RD
Acta Orthop Scand; 2001 Apr; 72(2):199-204. PubMed ID: 11372955
[No Abstract] [Full Text] [Related]
18. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
Hull RD; Pineo GF; Francis C; Bergqvist D; Fellenius C; Soderberg K; Holmqvist A; Mant M; Dear R; Baylis B; Mah A; Brant R
Arch Intern Med; 2000 Jul; 160(14):2208-15. PubMed ID: 10904465
[TBL] [Abstract][Full Text] [Related]
19. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
Heit JA; Elliott CG; Trowbridge AA; Morrey BF; Gent M; Hirsh J
Ann Intern Med; 2000 Jun; 132(11):853-61. PubMed ID: 10836911
[TBL] [Abstract][Full Text] [Related]
20. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.
J Bone Joint Surg Am; 1994 Aug; 76(8):1174-85. PubMed ID: 8056798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
